Aster DM Healthcare Ltd

- Aster DM Healthcare is opportunistic about expansions, both organic and inorganic, and will evaluate assets as they come along. - Post-GCC sale, the company still has cash available and is not highly leveraged, indicating capacity for further funding if needed. - Sunil Kumar mentioned around ₹1,500 crores of retained cash on the balance sheet. - No specific announcement of immediate new fundraising via debt or equity was mentioned during the call. - The company is focused on strategic investments in existing and new facilities, leveraging available cash and moderate leverage. - They indicated that any major financial moves would depend on opportunities and regulatory approvals, with no fixed timeline for new fundraising disclosed.

- QCIL plans to add about 1,250 beds by FY27, focusing on organic expansion in existing markets rather than new geographies. - There is ongoing investment in sprucing up certain hospitals (e.g., Care hospitals), with major makeover work largely nearing completion. - Specific expansions include adding 150 beds at Trivandrum (from 800 to 1,000+ beds), beds in Bhubaneswar, Hyderabad, Raipur, Chattogram, Vizag, and Nagercoil. - Investments are also targeted at enhancing clinical capabilities, including adding oncology services (e.g., new LINAC machine in Trivandrum). - Infrastructure improvements in Hyderabad have been significant in the last 6 months, focusing on tech and talent to increase profitability. - Aster is opportunistic on inorganic investments and uses cash (e.g., proceeds from GCC) for acquisitions; recent additions included 650 beds across two assets. - The combined entity is focusing on adding capacity and clinical talent, technology, and infrastructure to drive quality growth.

- QCIL plans to add approximately 1,200 to 1,300 beds by FY27 across various cities including Vizag, Hyderabad, Chattogram, Indore, Banjara, Trivandrum, and Bhubaneswar. - Aster has over 5,000 beds currently with 1,800 beds in the pipeline till FY27, including recent additions in Hyderabad and CMI hospital expansions. - Combined, Aster and QCIL are expected to continue strong revenue growth driven by organic expansion and selective inorganic acquisitions. - Aster has been growing at 25-30% top-line revenue growth and 35-40% bottom-line growth over last 3-4 years, QCIL growth around 18-20% top-line. - Occupancy rates have room to grow (e.g., Aster at ~68%, Trivandrum at ~78-79%), supporting volume expansion without hitting capacity constraints. - Continued focus on adding beds in existing micro-markets and ramping up new facilities. - Synergies between Aster and QCIL expected to drive margin improvement and revenue enhancements.

- Combined entity expects to reach ~25% EBITDA margin soon, up from Aster's 17% (FY24) and QCIL's 21-22% margins. (Page 14-15) - Synergies from the merger anticipated to boost EBITDA by 10-15%. (Page 14) - Revenue growth projected at 25%+ for Aster and 18-20% for QCIL over the next 3-5 years. (Page 10, 14) - Addition of approximately 3,300 beds planned by FY27 supports growth in volume and revenues. (Page 10) - Free cash flow roughly aligns with EBITDA, indicating strong cash generation. (Page 29) - Growth driven by both organic (capacity ramp-up) and opportunistic inorganic expansion. (Page 17) - Quality and complexity-driven ARPOB improvements expected to enhance profitability. (Page 15) Overall, strong margin expansion, revenue growth, and synergy realization underpin positive future earnings and EPS trajectory.

The transcript provided does not explicitly mention any current or expected order book or pending orders for Aster DM Healthcare or QCIL. The discussion mainly focuses on: - Expansion plans: Aster adding approximately 1,800 beds and QCIL adding about 1,250 beds by FY27. - Organic and inorganic growth strategies, including acquisitions and investments in existing properties. - Capacity utilization and continuous growth, with no mention of a "peak" capacity. - Focus on growing occupancy and improving ARPOB (Average Revenue Per Occupied Bed). There is no direct reference to a backlog of orders or pending projects in the transcript. The growth and expansion plans are ongoing and opportunistic.